Patient Awareness of CAR-T and Bispecific Antibody Treatments for Multiple Myeloma: Real-World Learnings and Disparities

被引：0
|
作者：
Adu, Yaw [1 ]
Das, Saurav [2 ]
Ailawadhi, Dhaani [3 ]
Fernandez, Andre [2 ]
Parrondo, Ricardo [2 ]
Roy, Vivek [2 ]
Sher, Taimur [2 ]
O'Connell, Sean [4 ]
Rasheed, Ahsan [2 ]
Chanan-Khan, Asher A. [2 ]
Ailawadhi, Sikander [2 ]
机构：
[1] Texas Tech Univ, Hlth Sci Ctr, Sch Med, Lubbock, TX USA
[2] Mayo Clin, Div Hematol Oncol, Jacksonville, FL USA
[3] Bolles Middle Sch, Jacksonville, FL USA
[4] Mayo Clin, Sch Continuous Profess Dev, Jacksonville, FL USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-189642
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
    Eugenia Zah
    Eunwoo Nam
    Vinya Bhuvan
    Uyen Tran
    Brenda Y. Ji
    Stanley B. Gosliner
    Xiuli Wang
    Christine E. Brown
    Yvonne Y. Chen
    Nature Communications, 11
  • [42] Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
    Sun, Fumou
    Cheng, Yan
    Peng, Bailu
    Xu, Hongwei
    van Rhee, Frits
    Janz, Siegfried
    Tricot, Guido
    Shaughnessy, John D., Jr.
    Zhan, Fenghuang
    BLOOD, 2021, 138
  • [43] Real-world evidence (RWE) study of CAR-T agents in leukemia and lymphoma patients.
    Lal, Lincy S.
    Blauer-Peterson, Cori
    Byfield, Stacey DaCosta
    Malin, Jennifer
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis
    Liang, Xiaojie
    Wang, Yufan
    Luo, Baiwei
    Lin, Bingyu
    Lu, WeiXiang
    Tian, Shengyu
    Liu, Dan
    Wang, Liang
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (11)
  • [45] HEMATOTOXICITY POST CAR-T CELL THERAPY: REAL-WORLD DATA ON RISK FACTORS AND OUTCOMES
    Bousiou, Zoi
    Kyriakou, Ioannis
    Vardi, Anna
    Mallouri, Despoina
    Gavriilaki, Eleni
    Demosthenous, Christos
    Spyridis, Nikolaos
    Panteliadou, Alkistis-Kyra
    Papchianou, Eleni
    Karavalakis, Georgios
    Yannaki, Evangelia
    Batsis, Ioannis
    Sakellari, Ioanna
    BONE MARROW TRANSPLANTATION, 2024, 59 : 218 - 219
  • [46] Canadian-made single domain antibody (sdAb) BCMA CAR-T cells for multiple myeloma
    Lindo, Lorenzo
    Waller, Daniel
    Wilkinson, Lauren
    Selleri, Silvia
    Arbabi-Ghahroudi, Mehdi
    McComb, Scott
    Bergsagel, Leif
    Chesi, Marta
    Hay, Kevin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S48 - S49
  • [47] Health Care Resource Utilization and Economic Burden of Cytokine Release Syndrome Management in Patients With Multiple Myeloma Receiving CAR-T Cell and Bispecific Antibody Therapies
    Rodriguez-Valdes, Cesar
    Jiao, Shiyin
    Yu, Junhua
    Kamalakar, Rajesh
    Cornell, R. Frank
    Sail, Kavita
    Bueno, Orlando
    Costa, Luciano
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S83 - S83
  • [48] CAR-T Cell Therapy: The State-of-the-Art of Evidence and Barriers in a Real-World Setting
    Kumar, A.
    Bajwa, A.
    Dowling, O.
    Sinha, S.
    Kalra, P.
    VALUE IN HEALTH, 2022, 25 (12) : S217 - S217
  • [49] Cognitive, neurological, and psychological presentation in patients planned for CAR-T therapy: a real-world approach
    Kuznetsova, Valeriya
    Oza, Harsh
    Rosenfeld, Hannah
    Sales, Carmela
    van der Linde, Samantha
    Roos, Izanne
    Roberts, Stefanie
    D'Aprano, Fiore
    Loi, Samantha M.
    Dowling, Mark
    Dickinson, Michael
    Kalincik, Tomas
    Harrison, Simon J.
    Anderson, Mary Ann
    Malpas, Charles B.
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (04) : 35 - 36
  • [50] CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth
    Berahovich, Robert
    Zhou, Hua
    Xu, Shirley
    Wei, Yuehua
    Guan, Jasper
    Guan, Jian
    Harto, Hizkia
    Fu, Shuxiang
    Yang, Kaihuai
    Zhu, Shuying
    Li, Le
    Wu, Lijun
    Golubovskaya, Vita
    CANCERS, 2018, 10 (09)
12345